Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0000950170-25-076398
Filing Date
2025-05-22
Accepted
2025-05-22 16:39:18
Documents
2
Period of Report
2025-05-22

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 1554
2 EX-24 dnth-ex24.htm EX-24 9556
  Complete submission text file 0000950170-25-076398.txt   12671
Mailing Address C/O DIANTHUS THERAPEUTICS, INC. 7 TIMES SQUARE, 43RD FLOOR NEW YORK NY 10036
Business Address
Read Simon (Reporting) CIK: 0001688199 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-38541 | Film No.: 25977805

Mailing Address 7 TIMES SQUARE 43RD FLOOR NEW YORK NY 10036
Business Address 7 TIMES SQUARE 43RD FLOOR NEW YORK NY 10036 929-999-4055
Dianthus Therapeutics, Inc. /DE/ (Issuer) CIK: 0001690585 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)